seed
Stage
1
Investors
About
Architect Therapeutics uses C-H bond activation chemistry to design and synthesize novel 3D small molecule drug scaffolds targeting difficult-to-drug disease mechanisms, primarily focusing on immunology and oncology.
Explore Architect Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.